Scientists reveal a new way cancer cells survive DNA damage
April 7, 2026
A cancer drug target already being investigated in clinical trials turns out to be doing something even more consequential than researchers realized.
A cancer drug target already being investigated in clinical trials turns out to be doing something even more consequential than researchers realized.
A virus that typically infects marine animals, such as shrimp and fish, has jumped to humans and is causing chronic eye disease in some people, according to a study published in the journal Nature Microbiology.
Encouraging 12-month pilot clinical study results will be presented by Key Opinion Leader Dr. Lowell Kabnick at the prestigious Charing Cross Vascular Symposium in London on Tuesday, April 21st, 2026.
Stereotaxis (NYSE:STXS) announced today that it received FDA 510(k) clearance for its Synchrony system.
With approval to study the transcatheter replacement device in patients with severe tricuspid regurgitation, VDyne is advancing a treatment to compete with Edwards Lifesciences’ Evoque system.
UCLA scientists have developed a simple and cost-effective blood test that, in early studies, shows promise in detecting multiple cancers, various liver conditions and organ abnormalities simultaneously by analyzing DNA fragments circulating in the bloodstream.
Results of a new study conclude that a pathology tool powered by artificial intelligence can predict whether a patient with extensive-stage small cell lung cancer will respond to platinum-based chemotherapy—before treatment has begun, and without additional biopsies. That means patients can avoid treatments that are unlikely to help them, have a chance to enroll earlier in clinical trials of newer drugs, and may get a clearer picture of their prognosis.
A novel vaccine platform has been developed to induce broad, protective immunity against numerous influenza virus infections, showing promise as an effective mucosal vaccine strategy, according to a study published by researchers in the Institute for Biomedical Sciences at Georgia State University.
Researchers have demonstrated a new class of low-cost, scalable sensors that can be used to monitor electrical activity in human cerebral organoids. Because electrical signals are key to understanding brain function, this advancement facilitates research into both neurodevelopment and genetic disorders such as Angelman syndrome.
A blood test could help identify people at higher risk of cognitive decline years before a traditional diagnosis is possible—according to University of East Anglia research published in the journal Gut Microbes.